Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18 janv. 2024 12h00 HE
|
Optinose, Inc.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and...
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
06 sept. 2022 12h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
11 août 2022 07h00 HE
|
Optinose, Inc.
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis...
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
13 juil. 2022 07h00 HE
|
Optinose, Inc.
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark...
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
08 juil. 2022 07h00 HE
|
Optinose, Inc.
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from...
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
13 juin 2022 07h00 HE
|
Optinose, Inc.
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times...
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
08 mars 2022 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects...
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
07 mars 2022 07h00 HE
|
Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...